ELISA Diagnostic Test Market to Reach US$ 2,271.23 million by 2030: The Insight Partners

AnchorAccording to our new research study on “ELISA Diagnostic Test Market Size and Forecast to 2030 – Global and Regional Analysis – by Adoption, Test Type, Application, and End User. The market is expected to grow from US$ 1,285.49 million in 2022 to US$ 2,271.23 million by 2030; it is estimated to register a CAGR of 7.37% from 2022 to 2030. Key driving factors behind the market development are the rising infectious diseases among animals and increasing incidence of human infections are the key driving factors behind the market development. However, incidents of product recalls are hampering the market growth.

Get Your Free Sample Copy Today | Click Here: https://www.theinsightpartners.com/sample/TIPRE00030120

AnchorGlobal ELISA Diagnostic Test market is segmented by region into North America, Europe, Asia-Pacific, Middle East and Africa, South and Central America. The North America ELISA diagnostic test market has been segmented into the US, Canada, and Mexico. The market growth in this region is attributed to the rising infectious diseases among humans, acting as a standalone factor positively influencing the growth of the market. Additionally, technological advancements in ELISA diagnostic kits further enhances the overall market growth during 2022-2030.

Increasing Incidence of Human Infections to Drive the ELISA Diagnostic Test Market

According to the CDC report published in 2022, every year, 4 in 10 adults in the US have two or more diseases, with 6 in 10 adults having a chronic disease. Among the chronic diseases, over 1.7 million cancer diagnoses are conducted, and nearly 600,000 cancer deaths are recorded every year in the US. Additionally, more than 34 million people in the US (10.5%) have diabetes, with 88 million adults (more than 1 in 3) having prediabetes, resulting in an increase in the risk of suffering from type 2 diabetes. The healthcare expenditure on death and disability due to chronic diseases accounts for US$ 4.1 trillion annually in the US alone.

In humans, ELISA test is used as a biomarker to detect cancer, infectious diseases, autoimmunity, endocrinology diagnosis, immunology & cytokines, cell adhesion molecules (CAMs), and others. ELISA testing helps detect cancer at the early stage of diagnostic processes, offering a better chance for patient survival and getting appropriate treatment initially. Therefore, demand for ELISA testing is high across the world owing resulting in market growth during the forecast period.

By adoption, the ELISA diagnostic test market is segmented into human and veterinary. The ELISA diagnostic test market, by adoption, is bifurcated into human and veterinary. The human segment held a larger market share in 2022 and the same segment is anticipated to register a higher CAGR of 7.88% during the forecast period. The veterinary segment was valued at US$ 446.67 million in 2022 and is expected to reach US$ 732.88 million by 2030. The growth rate of this segment is projected to be 6.39% during the forecast period. The adoption of ELISA tests in veterinary medicine is gaining importance owing to the growing prevalence of infectious diseases in domestic and wild animals. World Organization for Animal Health (WOAH) recommends ELISA tests for monitoring rabies-specific antibody titers, foot and mouth diseases, avian influenza disease, and many other viral infections in cattle, domestic, and poultry animals. For instance, in an article published in January 2023 by PubMed, the in-house ELISA (BukTi-Vet) developed to support post-vaccination monitoring in dogs was evaluated for its diagnostic performance compared to commercial ELISA kits.

Based on test type, market is segregated as sandwich ELISA, indirect ELISA, competitive ELISA, and multiple & portable ELISA. The indirect ELISA segment held a larger market share in 2022 and the same segment is anticipated to register a higher CAGR of 8.58% during the forecast period.

Based on application, market is categorized as autoimmune diseases, infectious disease, cancer diagnosis, protein quantification, and others. The infectious disease segment held the largest share of the market in 2022 and is anticipated to register the highest CAGR in the market during the forecast period.

The ELISA diagnostic test market, by end user, is categorized as hospitals & diagnostic centers, pharmaceutical & biotechnology companies, veterinary hospital & diagnostic laboratories, and others. The hospital & diagnostic centers segment held the largest share of the market in 2022

Major players in the ELISA diagnostic test market include B Braun SE; DePuy Synthes Inc.; Medtronic Plc; Siemens Healthineers AG; Stryker Corp.; ZimmerBiomet Holdings Inc.; Brainlab AG; CASCINATION; HEMOSTASIS, LLC; Corin Group; and GE HealthCare Technologies Inc. These leading players adopt strategies such as the launch of new products, expansion and diversification of their market presence, and expansion of new customer base for tapping prevailing business opportunities.

About US

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, ELISA Diagnostic Test, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Food and Beverages, Consumers and Goods, Chemicals and Materials.

Contact US

Contact Person : Ankit Mathur

Phone : +1-646-491-9876

E-mail : [email protected]